Active Ingredient History
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Chronic Pain (Phase 3)
Familial Hypophosphatemic Rickets (Phase 4)
Fibrous Dysplasia of Bone (Phase 2)
Genetic Diseases, X-Linked (Phase 3)
Hypophosphatemia (Phase 3)
Neoplasms (Phase 4)
Nevus (Phase 4)
Osteomalacia ()
Rare Diseases (Phase 4)
Rickets, Hypophosphatemic (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
